Turn Biotechnologies raises Series B funding

This was a company funding announcement, not a clinical study. Turn Biotechnologies said it raised $72 million to develop treatments using messenger RNA, or temporary instructions that tell cells which proteins to make. The company aims to use these treatments to restore some youthful cell functions. The announcement reported no completed human trial, health improvement, or lifespan benefit.

What this means for you: This funding supports further research but does not show that the treatment is safe or effective. Do not buy or use an anti-aging product based on this announcement alone.